0001567619-20-016247.txt : 20200901 0001567619-20-016247.hdr.sgml : 20200901 20200901173150 ACCESSION NUMBER: 0001567619-20-016247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200901 DATE AS OF CHANGE: 20200901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Innoviva, Inc. CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38670 FILM NUMBER: 201155203 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 500 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 6502389600 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 500 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER NAME: FORMER CONFORMED NAME: THERAVANCE INC DATE OF NAME CHANGE: 20020207 FORMER NAME: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001724344 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824592913 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 810-0120 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Entasis Therapeutics Ltd DATE OF NAME CHANGE: 20171204 4 1 doc1.xml FORM 4 X0306 4 2020-09-01 0 0001724344 Entasis Therapeutics Holdings Inc. ETTX 0001080014 Innoviva, Inc. 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 0 0 1 0 Common Stock 2020-09-01 4 P 0 4672897 2.675 A 18672897 D Warrants to Purchase Common Stock 2.675 2020-09-01 4 P 0 4672897 2.675 A 2020-09-01 2025-09-01 Common Stock 4672897 18672897 D See Exhibit 99.1 INNOVIVA, INC.; By: /s/ Pavel Raifeld; Chief Executive Officer 2020-09-01 EX-99.1 2 i37090993.htm EXPLANATION OF RESPONSES

Explanation of Responses

(1)

As reflected in the Amendment No. 3 to Schedule 13D filed by Innoviva, Inc. (the “Reporting Person”) with the U.S. Securities and Exchange Commission on September 1, 2020 (the “Schedule 13D/A”), in connection the closing that occurred on September 1, 2020 pursuant to a securities purchase agreement, dated as of August 27, 2020 (the “Purchase Agreement” and, such closing, the “Closing”), by and among Entasis Therapeutics Holdings Inc. (the “Issuer”) and the purchasers named therein, including the Reporting Person, the Reporting Person acquired 4,672,897 shares of common stock of the Issuer (“Shares”) and warrants to purchase an additional 4,672,897 Shares (“Warrants”) as set forth in this Form 4. As a result of the Closing, the Reporting Person beneficially owns 37,345,794 Shares. The Schedule 13D/A filed by the Reporting Person is incorporated by reference in this Form 4; any description herein of the Schedule 13D/A is qualified in its entirety by reference to the Schedule 13D/A so filed by the Reporting Person.